AGENUS INC (AGEN) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$6.30

From 52W high−37.76%

Volume734858.00

Market cap$279.10M

P/E (TTM)2.3x

P/S (TTM)2.1x

Div yield—

Key dataOct 19, 2026

Open

$6.30

From 52W high

−37.76%

Volume

734858.00

Market cap

$279.10M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.9x

P/E (TTM)

2.3x

RSI (14)

35.0

MomentumView details →

1D Return

+2.32%

YTD Return

+95.03%

SummaryUpdated Jun 1, 2026

Agenus Inc. (NASDAQ:AGEN) is a clinical-stage immuno-oncology biotechnology company founded in 1994 and headquartered in Lexington, Massachusetts. Originally incorporated as Antigenics Inc., the company changed its name to Agenus in January 2011. Agenus focuses on discovering and developing innovative cancer immunotherapies, with its lead program being the combination therapy of botensilimab and balstilimab (BOT/BAL) showing promising results in treating various solid tumors, particularly colorectal cancer. The company went public in February 2000 and has built a comprehensive pipeline of immuno-oncology treatments while also developing proprietary antibody discovery platforms.

Ask drillr about AGENUS INC →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

2.3x

EV/EBITDA

1.9x

EV/Sales

2.2x

P/S (TTM)

2.1x

P/B (TTM)

−1.4x

ProfitabilityView details →

Gross Margin

99.52%

Net Margin

69.34%

EBITDA Margin

117.39%

ROE (TTM)

−46.22%

ROA (TTM)

53.28%

Asset Turnover

0.74x

GrowthView details →

Revenue YoY

+30.47%

EPS YoY

+137.98%

FCF YoY

+22.97%

Revenue CAGR 3Y

+5.22%

EPS CAGR 3Y

+99.97%

EBITDA YoY

+307.89%

MomentumView details →

1D Return

+2.32%

YTD Return

+95.03%

1Y Return

+38.55%

RSI (14)

35.0

vs 50D SMA

−20.53%

vs 200D SMA

+27.43%

Capital & dividendView details →

Debt/Equity

−0.20x

Current Ratio

0.34x

Quick Ratio

0.34x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.01

EPS Surprise

−122.22%

Beats (12Q)

5/12

Next Q EPS Est

−$0.30

Avg Surprise (4Q)

−1.60%

Rev Surprise

1.47%

Financials snapshotView financials →

Revenue (TTM)

132.69M

Net Income (TTM)

92.01M

Op. CF (TTM)

−98.50M

Next earningsNov 9, 2026 →

Latest newsMore news →

Agenus Inc. announced three-year follow-up results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating botensilimab plus balstilimab, reporting 48% estimated three-year survival, at IGCS 2026.16d ago

Similar companies

Contineum Therapeutics, Inc. Class A Common StockCTNM Surrozen, Inc.SRZN Fulcrum Therapeutics, Inc.FULC X4 Pharmaceuticals, Inc.XFOR Cypherpunk Technologies Inc.CYPH Shanghai Bio-heart Biological Technology Co., Ltd.02185.HK Find similar companies →

Latest newsMore news →

Armenia’s Ministry of Health granted marketing authorizations for Agenus’ Botvymo (botensilimab) and Evamplix (balstilimab), approved in combination to treat adults with previously treated MSS metastatic colorectal cancer without active liver metastases.11d ago Agenus Inc. announced three-year follow-up results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating botensilimab plus balstilimab, reporting 48% estimated three-year survival, at IGCS 2026.16d ago Agenus Inc. announced that two posters on botensilimab plus balstilimab and agenT-797 research in colorectal cancer were accepted for presentation at the SITC 2026 Annual Meeting in Phoenix, Arizona, November 4-8, 2026.17d ago